Miltenyi Biomedicine GmbH
This is a single-center, open-label, single-arm, pilot clinical study using TCRα/β and CD45RA depleted stem cell grafts from haploidentical donors for hematopoietic cell transplantation in 12 to 18 adult patients.
Inclusion Criteria: * Patients, between 18 years to 75 years of age, with high-risk hematological malignancy requiring an allogeneic hematopoietic stem cell transplantation (AlloHCT), but do not have an HLA-matched donor available Exclusion Criteria: * \<3 months after preceding autologous transplantation or prior AlloHCT * History of neurological impairment (active seizures, severe peripheral neuropathy, signs of leukoencephalopathy, active CNS infection) * Active fungal infections with radiological and clinical progression * Liver function abnormalities with bilirubin \>2 mg/dL and elevat…
PBSC grafts from haploidentical donors depleted of TCRaβ+ cells and CD45RA+ cells using CliniMACS Prodigy® will be infused into patients intravenously (IV)
Arctuva estimate
Verify or correct the compensation shown for this listing.